These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

124 related items for PubMed ID: 8835287

  • 1. Differential interactions of cytochalasins with P-glycoprotein.
    Zilfou JT, Smith CD.
    Oncol Res; 1995; 7(9):435-43. PubMed ID: 8835287
    [Abstract] [Full Text] [Related]

  • 2. Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance.
    Smith CD, Carmeli S, Moore RE, Patterson GM.
    Cancer Res; 1993 Mar 15; 53(6):1343-7. PubMed ID: 8095179
    [Abstract] [Full Text] [Related]

  • 3. Reversal of multiple drug resistance by tolyporphin, a novel cyanobacterial natural product.
    Smith CD, Prinsep MR, Caplan FR, Moore RE, Patterson GM.
    Oncol Res; 1994 Mar 15; 6(4-5):211-8. PubMed ID: 7841544
    [Abstract] [Full Text] [Related]

  • 4. Welwitindolinone analogues that reverse P-glycoprotein-mediated multiple drug resistance.
    Smith CD, Zilfou JT, Stratmann K, Patterson GM, Moore RE.
    Mol Pharmacol; 1995 Feb 15; 47(2):241-7. PubMed ID: 7870031
    [Abstract] [Full Text] [Related]

  • 5. Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.
    Trendowski M, Christen TD, Acquafondata C, Fondy TP.
    BMC Cancer; 2015 Sep 10; 15():632. PubMed ID: 26357852
    [Abstract] [Full Text] [Related]

  • 6. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM, Liang YJ, Ruan JW, Ding Y, Wang XW, Shi Z, Gu LQ, Yang XP, Fu LW.
    J Pharm Pharmacol; 2004 Aug 10; 56(8):1061-6. PubMed ID: 15285852
    [Abstract] [Full Text] [Related]

  • 7. Microfilament depletion and circumvention of multiple drug resistance by sphinxolides.
    Zhang X, Minale L, Zampella A, Smith CD.
    Cancer Res; 1997 Sep 01; 57(17):3751-8. PubMed ID: 9288783
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein.
    Garrigues A, Nugier J, Orlowski S, Ezan E.
    Anal Biochem; 2002 Jun 01; 305(1):106-14. PubMed ID: 12018951
    [Abstract] [Full Text] [Related]

  • 11. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction.
    Martin C, Berridge G, Higgins CF, Callaghan R.
    Br J Pharmacol; 1997 Oct 01; 122(4):765-71. PubMed ID: 9375975
    [Abstract] [Full Text] [Related]

  • 12. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance.
    Leveille-Webster CR, Arias IA.
    Clin Cancer Res; 1996 Apr 01; 2(4):695-706. PubMed ID: 9816220
    [Abstract] [Full Text] [Related]

  • 13. Modulation of vindesine and doxorubicin resistance in multidrug-resistant pleural mesothelioma cells by tumor necrosis factor-alpha.
    Licht T, Lübbert M, Martens C, Bross KJ, Fiebig HH, Mertelsmann R, Herrmann F.
    Cytokines Mol Ther; 1995 Jun 01; 1(2):123-32. PubMed ID: 9384669
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Differential interactions of Pgp inhibitor thaliblastine with adriamycin, etoposide, taxol and anthrapyrazole CI941 in sensitive and multidrug-resistant human MCF-7 breast cancer cells.
    Chen G, Teicher BA, Frei E.
    Anticancer Res; 1996 Jun 01; 16(6B):3499-505. PubMed ID: 9042212
    [Abstract] [Full Text] [Related]

  • 17. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
    Sulová Z, Macejová D, Seres M, Sedlák J, Brtko J, Breier A.
    Toxicol In Vitro; 2008 Feb 01; 22(1):96-105. PubMed ID: 17920233
    [Abstract] [Full Text] [Related]

  • 18. New 4-aryl-1,4-dihydropyridines and 4-arylpyridines as P-glycoprotein inhibitors.
    Zhou XF, Zhang L, Tseng E, Scott-Ramsay E, Schentag JJ, Coburn RA, Morris ME.
    Drug Metab Dispos; 2005 Mar 01; 33(3):321-8. PubMed ID: 15585608
    [Abstract] [Full Text] [Related]

  • 19. Downregulation of JNK/SAPK activity is associated with the cross-resistance to P-glycoprotein-unrelated drugs in multidrug-resistant FM3A/M cells overexpressing P-glycoprotein.
    Kang CD, Ahn BK, Jeong CS, Kim KW, Lee HJ, Yoo SD, Chung BS, Kim SH.
    Exp Cell Res; 2000 Apr 10; 256(1):300-7. PubMed ID: 10739677
    [Abstract] [Full Text] [Related]

  • 20. Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket.
    Loo TW, Bartlett MC, Clarke DM.
    Biochem J; 2006 Oct 15; 399(2):351-9. PubMed ID: 16813563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.